The Complete Guide to FDA Approved Drugs for Ulcerative Colitis

Living with Ulcerative Colitis (UC) means navigating a condition that never fully leaves your mind. The unpredictable flare-ups, the discomfort, and the constant uncertainty can feel overwhelming. But here's the encouraging news: the science of treating UC has advanced dramatically. A new wave of FDA-approved medications is reshaping what remission actually looks like - with more convenient, targeted, and personalized options than ever before. If you or someone you care for is managing UC, understanding what's now available could change everything.

What Is Ulcerative Colitis - And Why Treatment Matters So Much

Ulcerative Colitis is a chronic inflammatory bowel disease (IBD) that causes inflammation and ulcers in the lining of the large intestine and rectum. Unlike a temporary stomach illness, UC is a lifelong condition that cycles between flares and remission.

Without effective treatment, ongoing inflammation can lead to serious complications, including bowel damage, nutritional deficiencies, and an increased risk of colorectal cancer. The goal of modern therapy isn't just symptom relief - it's achieving and sustaining deep remission to protect long-term health.

The New Generation of FDA-Approved UC Treatments

The FDA has been actively expanding the toolkit available to gastroenterologists and patients. Here's a breakdown of the most significant recent approvals:

Mirikizumab (Omvoh) - Simplified Monthly Maintenance

Originally approved for UC in 2023, Omvoh received an important update in October 2025. The FDA approved a new single-injection, once-monthly maintenance regimen (200 mg/2 mL). What changed? The previous maintenance phase required two injections per month. Now, patients can manage their condition with just one self-administered, citrate-free injection monthly - making it far easier to stay consistent with treatment at home.

1. Drug class: IL-23p19 Inhibitor (biologic)
2. Who it's for: Adults with moderately to severely active UC
3. Key benefit: Streamlined at-home dosing regimen

Guselkumab (Tremfya) - The First Fully Subcutaneous IL-23 Inhibitor for UC

Tremfya made history in September 2025 when the FDA approved a fully subcutaneous (SC) induction regimen. This is a significant milestone: Tremfya became the first and only IL-23 inhibitor that allows patients to begin their treatment entirely through self-administered under-the-skin injections - no IV infusions at a clinic required.

1. Drug class: Dual-acting IL-23 Inhibitor (biologic)
2. Who it's for: Adults with moderately to severely active UC
3. Key benefit: Removes the barrier of clinic-based IV infusion from day one

Upadacitinib (Rinvoq) - Earlier Access to an Oral Option

For patients who prefer a pill over an injection, Rinvoq is a once-daily oral tablet that has shown strong efficacy in UC. In October 2025, the FDA updated Rinvoq's label to allow it to be prescribed earlier in the treatment timeline - before patients need to try or fail a TNF blocker biologic.

1. Drug class: JAK Inhibitor (oral pill)
2. Who it's for: Adults with moderate-to-severe UC who have received at least one prior approved systemic therapy
3. Key benefit: Faster access to a highly effective, convenient oral therapy

Next-Generation Hydrocortisone Acetate (ngHCA) - A Targeted Option for Rectal UC

Not all UC affects the entire colon. Many patients experience inflammation primarily in the rectum - a form known as ulcerative proctitis. In April 2026, the FDA accepted a New Drug Application (NDA) for a 90 mg next-generation hydrocortisone acetate suppository specifically designed for this lower-bowel form of UC. If approved by its target action date later in 2026, it would be the first FDA-approved hydrocortisone acetate suppository for rectal UC, offering precise, localized relief.

1. Drug class: Topical Corticosteroid
2. Who it's for: Patients with UC affecting the rectum
3. Key benefit: Highly targeted, localized treatment approach

The Bigger Picture: What's Driving These Advancements

The common thread across all these recent FDA developments is a shift toward patient convenience and precision. The medical community has recognized that a treatment plan patients can realistically stick to is more effective than a theoretically superior one that's difficult to follow.

Key trends shaping UC treatment in 2026 include:

1. Moving away from IV infusions toward at-home self-injection and oral options
2. Earlier access to advanced therapies rather than requiring patients to exhaust older options first
3. Targeted biologics that focus on specific inflammatory pathways (like IL-23) rather than broadly suppressing the immune system
4. Localized treatments for patients whose disease is limited to specific parts of the colon

How Are UC Drugs Categorized?

Understanding drug categories helps patients have more informed conversations with their doctors. Here's a simplified overview:

1. Aminosalicylates (5-ASAs): Often a first-line treatment for mild-to-moderate UC (e.g., mesalamine)
2. Corticosteroids: Used for short-term flare management, not long-term maintenance
3. Immunomodulators: Medications like azathioprine that reduce immune activity
4. Biologics: Targeted therapies including TNF inhibitors (infliximab, adalimumab), integrin inhibitors (vedolizumab), and IL-12/23 or IL-23 inhibitors (ustekinumab, mirikizumab, guselkumab)
5. Small Molecule Drugs (JAK Inhibitors): Oral options like tofacitinib and upadacitinib

What Should You Ask Your Doctor?

If you're currently being treated for UC - or wondering whether your current plan is still the best fit - these are worth bringing up at your next appointment:

1. Is my current treatment achieving deep remission, or just managing symptoms?
2. Are there newer approved options I might be eligible for?
3. Would a fully subcutaneous biologic or oral therapy better fit my lifestyle?
4. Could a more targeted therapy based on where my inflammation occurs be appropriate?

Finding the Right Treatment for Your Specific Situation

The right UC medication depends on the severity of your disease, where inflammation occurs in your colon, your medical history, other medications you take, and your personal preferences around injections vs. pills vs. infusions. What works well for one patient may not be the ideal choice for another.

That's why understanding the broader landscape of approved treatments is so valuable - it empowers you to participate actively in decisions about your own care.

Staying Informed About UC Treatment Options

The field of Ulcerative Colitis treatment is evolving faster than ever. New approvals, updated guidelines, and expanded drug indications continue to emerge. Patients, caregivers, and anyone newly diagnosed with UC have more reason for optimism today than at any point in the history of the disease.

Exploring the latest information about approved therapies - including how different drug classes work, which conditions they treat, and what clinical studies have shown - is a powerful first step toward making informed decisions alongside your healthcare team.